Insider · CIK 0001742727
Yaron Naos
Files at PLX (Protalix BioTherapeutics, Inc.). First filing -, latest -.
Yaron Naos files SEC Form 4 as COO at PLX (Protalix BioTherapeutics, Inc.). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.
A track record needs three past buys with six months of prices behind them; Yaron Naos has 0, so none is measured yet.
Signals
This insider’s open-market buys and sells, scored.
Transactions
Every row this insider has filed, 4 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Sep 3, 2026 | PLX Protalix BioTherapeutics, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +112,000 | $0.00 | $0 | 112,000 | 39 d ago |
| Sep 3, 2026 | PLX Protalix BioTherapeutics, Inc. | AGrant or award Restricted Stock Unitsderivative | +56,000 | $0.00 | $0 | 56,000 | 39 d ago |
| Sep 3, 2025 | PLX Protalix BioTherapeutics, Inc. | AGrant or award Common Stockindirect: By Trust | +25,000 | - | - | 225,817 | Sep 4, 2025 |
| Sep 3, 2025 | PLX Protalix BioTherapeutics, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +50,000 | $0.00 | $0 | 50,000 | Sep 4, 2025 |
Questions about Yaron Naos
Answered from the filings on this page, as of the latest one.
Is Yaron Naos buying or selling?
Yaron Naos has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.
How did Yaron Naos's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Yaron Naos has 0.
Where does Yaron Naos file Form 4?
Yaron Naos has filed Form 4 at PLX (Protalix BioTherapeutics, Inc.) as Sr. VP, Operations. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.